Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  American Journal of Cardiology

• Publication date

  2007-02-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.AMJCARD.2006.11.010PMID 17307062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

  2006cited by this paper
• PPARδ: a dagger in the heart of the metabolic syndrome

  2006cited by this paper
• Clinical trials report

  2006cited by this paper
• Field of confusion: future prospects for fibrate therapy in cardiovascular disease.

  2006cited by this paper
• Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

  2006cited by this paper
• PPAR delta: a dagger in the heart of the metabolic syndrome.

  2006cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

  2005cited by this paper
• Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1 Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400400-JLR200

  2005cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.

  2005cited by this paper
• Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.

  2005cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

  2005cited by this paper
• Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.

  2005cited by this paper
• Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

  2005cited by this paper
• Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.

  2005cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Pharmacological PPARγ Stimulation in Contrast to Beta Cell Stimulation Results in an Improvement in Adiponectin and Proinsulin Intact Levels and Reduces Intima Media Thickness in Patients with Type 2 Diabetes

  2005cited by this paper
• High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease.

  2004cited by this paper
• The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.

  2004cited by this paper
• Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.

  2004cited by this paper
• A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

  2004cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.

  2004cited by this paper
• Current overview of statin-induced myopathy.

  2004cited by this paper
• Clinical Trials and Lipid Guidelines for Type II Diabetes

  2004cited by this paper
• Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial

  2004cited by this paper
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

  2004cited by this paper
• Increasing HDL Cholesterol Levels.

  2004cited by this paper
• Expression and Regulation of Multiple Murine ATP-binding Cassette Transporter G1 mRNAs/Isoforms That Stimulate Cellular Cholesterol Efflux to High Density Lipoprotein*

  2004cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  2003cited by this paper
• Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.

  2003cited by this paper
• An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.

  2003cited by this paper
• Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

  2003cited by this paper
• Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

  2003cited by this paper
• Liver X receptor signaling pathways in cardiovascular disease.

  2003cited by this paper
• Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

  2003cited by this paper
• Muscle-specific Pparg deletion causes insulin resistance

  2003cited by this paper
• Glitazones and heart failure: critical appraisal for the clinician.

  2003cited by this paper
• Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion

  2002cited by this paper
• Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia

  2002cited by this paper
• Combination therapy for dyslipidemia: safety and regulatory considerations.

  2002cited by this paper
• Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

  2002cited by this paper
• World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic.

  2002cited by this paper
• The rationale for combination therapy.

  2002cited by this paper
• Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.

  2002cited by this paper
• Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.

  2002cited by this paper
• ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

  2002cited by this paper
• Effects of fibrates on metabolism of statins in human hepatocytes.

  2002cited by this paper
• Pulmonary Edema Associated with Rosiglitazone and Troglitazone

  2001cited by this paper
• A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport

  2001cited by this paper
• Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.

  2001cited by this paper
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

  2000cited by this paper
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

  2000cited by this paper
• Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

  1999cited by this paper
• Pulmonary edema associated with troglitazone therapy.

  1999cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development

  1999cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

  1999cited by this paper
• PPAR gamma is required for placental, cardiac, and adipose tissue development.

  1999cited by this paper
• Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.

  1998cited by this paper
• Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

  1998cited by this paper
• Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes.

  1998cited by this paper
• Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment

  1992cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Verbenalin attenuates hepatic damage and mitochondrial dysfunction in alcohol-associated steatohepatitis by regulating MDMX/PPARα-mediated ferroptosis.

  2023cites this paper
• CircRNF111 Contributes to Adipocyte Differentiation by Elevating PPARγ Expression via miR-27a-3p

  2022cites this paper
• Effects of peroxisome proliferator activated receptor gamma (PPARγ) agonist on fasting model applied neuron cultures

  2021cites this paper
• Electroacupuncture combined with acarbose improves insulin sensitivity via peroxisome proliferator–activated receptor γ activation and produces a stronger glucose-lowering effect than acarbose alone in a rat model of steroid-induced insulin resistance

  2020cites this paper
• Potential role of Peroxisome Proliferator Activated Receptor gamma analogues in regulation of endothelial progenitor cells in diabetes mellitus: An overview.

  2019cites this paper
• Superior single nucleotide polymorphisms that contribute to two main routes of the fatty acid synthesis pathway in Korean cattle

  2018cites this paper
• Two Novel SNPs of PPARγ Significantly Affect Weaning Growth Traits of Nanyang Cattle

  2018cites this paper
• Capsaicinoids improve consequences of physical activity

  2018cites this paper
• 15 hz Electroacupuncture at St36 Improves Insulin Sensitivity and Reduces Free Fatty Acid Levels in Rats with Chronic Dexamethasone-Induced Insulin Resistance

  2016cites this paper
• Intracellular signalling pathways associated with the glucose-lowering effect of ST36 electroacupuncture in streptozotocin-induced diabetic rats

  2015cites this paper
• Diabetes mellitus tipo 2: qual o papel da insulina na expressão de NF-kappaB, PPARγ e CD36? Type 2 diabetes: What is the role of insulin in NF-kappaB, PPARγ and CD36 expression?

  2014cites this paper
• The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.

  2013cites this paper
• Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetes mellitus patients: a double-blind randomised clinical trial.

  2013cites this paper
• Peroxisome proliferator-activated receptor (PPAR) isoforms in coronary heart disease

  2013cites this paper
• Koroner kalp hastaliğinda peroksizom proliferatör-aktive reseptör (PPAR) izoformlari

  2013cites this paper
• AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats

  2012cites this paper
• A missense mutant of the PPAR-γ gene associated with carcass and meat quality traits in Chinese cattle breeds.

  2012cites this paper
• Modified methylenedioxyphenol analogs lower LDL cholesterol through induction of LDL receptor expression[S]

  2012cites this paper
• Lipoprotein metabolism in nonalcoholic fatty liver disease

  2012cites this paper
• Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.

  2012cites this paper
• DIFFERENT ANIMAL MODELS FOR DRUGS WITH POTENTIAL AN TIDIABETIC PROPERTIES

  2011cites this paper
• DIFFERENT ANIMAL MODELS FOR DRUGS WITH POTENTIAL ANTIDIABETIC PROPERTIES Shah

  2011cites this paper
• Génération de progéniteurs hépatiques dérivés de cellules souches : application à l’hypercholestérolémie familiale

  2011cites this paper
• Some Common Antidiabetic Plants of the Indian Subcontinent

  2010cites this paper
• Integrating pathway analysis and genetics of gene expression for genome-wide association studies.

  2010cites this paper
• Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.

  2010cites this paper
• Effect of Pioglitazone on Platelet Aggregation in a Healthy Cohort

  2010cites this paper
• The PPAR-γ Agonist, Darglitazone, Restores Acute Inflammatory Responses to Cerebral Hypoxia–Ischemia in the Diabetic ob/ob Mouse

  2010influential citation
• Antihyperglycemic, antihyperlipidemic and antioxidant effects and the probable mechanisms of action of Ruta graveolens infusion and rutin in nicotinamide-streptozotocin-induced diabetic rats.

  2010cites this paper
• Three novel SNPs in the coding region of PPARγ gene and their associations with meat quality traits in cattle

  2010cites this paper
• Antihyperglycemic activity of methanolic extract of Madhuca longifolia bark.

  2010influential citation
• N-3 fatty acids in glucose metabolism and insulin sensitivity.

  2009influential citation
• Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies

  2009cites this paper
• Treatment of obesity and type 2 diabetes with PPARα agonists – effects on myocardial metabolism, gene expression and ventricularfunction

  2009cites this paper
• Current strategies for the inhibition of hepatic glucose production in type 2 diabetes.

  2009cites this paper
• Revisión N-3 fatty acids in glucose metabolism and insulin sensitivity

  2009influential citation
• Role of coactivator PGC-1α in energy balance. Importance in the production of beef cattle.

  2008influential citation
• Papel del coactivador PGC-1α en el balance energético. Importancia en la producción de bovinos de engorda.

  2008cites this paper
• Regulation der Fettgewebsinflammation durch Liganden von Peroxisome Proliferator Activated Receptor γ

  2008cites this paper
• Role of lipoprotein lipase in triglyceride metabolism: potential therapeutic target

  2008cites this paper
• Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients

  2008cites this paper
• Neuronal Peroxisome Proliferator-Activated Receptor γ Signaling: Regulation by Mood-Stabilizer Valproate

  2008cites this paper
• Animal models to test drugs with potential antidiabetic activity.

  2008cites this paper
• Role of Interleukin-6 in the Control of DNA Synthesis of Hepatocytes: Involvement of PKC, p44/42 MAPKs, and PPARδ

  2008cites this paper
• Fenofibrate: treatment of hyperlipidemia and beyond

  2008cites this paper
• Peroxisome proliferator-activated receptors and the metabolic syndrome

  2008cites this paper
• Non-Alcoholic Fatty Liver Disease : A clinical and histopathological study

  2008cites this paper
• Human cholesterol metabolism and therapeutic molecules

  2007influential citation